SciSparc, Clearmind Medicine reflect on collaboration in 2023

SciSparc (SPRC) reflects on the collaboration in 2023 with Clearmind Medicine Inc. (CMND). Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc. The patent applications are for novel proprietary combinations of lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine and Palmitoylethanolamide and novel proprietary combinations of 3,4-Methylenedioxymethamphetamine, Ibogaine, Ketamine, and PEA. PEA is the active ingredient of SciSparc’s proprietary CannAmide. The companies said, “The patent applications represent a commitment by SciSparc and Clearmind to offer patients safer and more effective treatments than those available today partly by strengthening their IP portfolios to broaden the therapeutic psychedelic toolbox for patients with mental health disorders that require transformative medicines and by developing treatments that offer synergy, efficacy and safety, while reducing the total cost.” As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind.